Transcranial Magnetic Stimulation for Mild Cognitive Impairment
This study is testing a non-invasive brain stimulation called accelerated intermittent theta burst stimulation (iTBS) using a device called a MagVenture MagPro TMS System. It aims to find the best dose of iTBS to improve depression and thinking abilities in people aged 60-85 who have mild cognitive impairment (MCI) and depression. You would receive either the active iTBS treatment or a sham (inactive) treatment. Researchers will measure changes in your depression symptoms using a scale and your thinking abilities using a special test battery. The study is trying to understand how different doses of iTBS work before planning larger studies to see if it can prevent dementia. The current status of this study is unclear, and it plans to enroll 60 participants.
- Study design
- This interventional study plans to enroll 60 participants. It compares active accelerated iTBS treatment to a sham (inactive) treatment.
- What's involved
- You would have multiple treatment sessions. Your depression and thinking abilities will be assessed at Week 0 (before treatment), Week 3 (1 week after treatment), Week 10 (8 weeks after treatment), and Week 26 (6 months after treatment).
- Compensation
- Not stated in the trial record.
- Follow-up
- Your progress will be followed for 26 weeks (6 months) after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Transcranial Magnetic Stimulation for MCI
At a glance
Conditions
NCT05992831
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Medical University of South Carolina
Charleston, South Carolinastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Andreana Benitez, PhD · PRINCIPAL_INVESTIGATOR · Medical University of South Carolina
- Lisa McTeague · PRINCIPAL_INVESTIGATOR · Medical University of South Carolina
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change in Geriatric Depression Scale (GDS) raw scoreWeek 0 (1 week pre-treatment), Week 3 (1 week post-treatment), Week 10 (8 weeks post-treatment), and Week 26 (6 months post-treatment)
The GDS is a \~3 minute self-report questionnaire of depression symptoms to which respondents answer yes/no (range=0-30, where higher scores indicate greater depression severity). Co-Participants will complete an informant-reported short form.
- Change in NIH Toolbox-Cognition Battery (NIHTB-CB) Fluid CompositeWeek 0 (1 week pre-treatment), Week 3 (1 week post-treatment), Week 10 (8 weeks post-treatment), and Week 26 (6 months post-treatment)
The NIHTB-CB is a performance-based, iPad-administered \~30-minute suite of 7 tests that ascertain abilities in different cognitive domains (i.e. executive function, episodic memory, working memory, processing speed, language). It was developed using advanced psychometric techniques to minimize measurement error and produces normed subtest and composite scores. We will use the fully-corrected T-score (range T=0-100; Mean T=50, SD=10; higher scores indicating better cognition) of the Fluid Cognition Composite (normed for age, sex, years of education, and race/ethnicity) to more accurately reflect global, dynamic thinking abilities that reflect the presence of disease or the impact of interventions, and not premorbid influences on test scores.